Aurora Cannabis Inc Stock Price, News & Analysis

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) has issued a statement addressing two false articles published on Investing.com. The first article falsely claimed Aurora agreed to acquire New Zealand's MedLeaf Therapeutics, while the second incorrectly stated the company entered a strategic partnership with MediPharm GmbH for cannabis distribution in Germany and EU markets. Aurora explicitly denies both claims, stating it has not engaged in discussions with either company regarding acquisitions or partnerships. The articles were reportedly generated with AI support and reviewed by an editor. Aurora has launched an investigation into these false publications and emphasizes that any material corporate transactions will be announced directly by the company. The company confirms it holds no material non-public information and warns investors against relying on Investing.com for Aurora-related news.

Aurora Cannabis (NASDAQ: ACB) has officially denied rumors regarding its alleged acquisition of New Zealand-based MedLeaf Therapeutics. The company explicitly stated it has not entered into any agreement with MedLeaf Therapeutics, nor has it engaged in any discussions about a potential business combination. The statement comes in response to incorrect information published on a news website. Aurora also noted that it had filed its Q4 and fiscal year 2025 financial statements and management's discussion and analysis earlier that day, with all relevant information available on the company's website and regulatory platforms SEDAR+ and EDGAR.

Aurora Cannabis (ACB) reported strong fiscal year 2025 results with record annual global medical cannabis net revenue of $244.4M, up 39% YoY. Q4 2025 delivered total net revenue of $90.5M, a 34% increase YoY, driven by 48% growth in medical cannabis and 32% growth in plant propagation. The company achieved record adjusted EBITDA of $49.7M (261% YoY growth) and generated positive annual free cash flow of $9.9M. Medical cannabis represented 75% of Q4 revenue at $67.8M, with international revenue doubling to 61% of global medical cannabis sales. The company maintains a strong balance sheet with $185.3M cash and a debt-free cannabis business. Q4 adjusted gross margin reached 62%, with medical cannabis margins at 70%. Consumer cannabis revenue declined 20% to $8.2M as the company prioritized higher-margin medical sales.

Aurora Cannabis (NASDAQ: ACB) has expanded its medical cannabis portfolio in Australia with the launch of IndiMed TEMPO 22 through its subsidiary MedReleaf Australia. The expansion includes two new cultivars: Lemon Laser (Sativa) and Pickled Petrol (Indica), both featuring 22% THC and less than 1% CBD, available in 15g dried cannabis format. IndiMed is currently one of the most prescribed medical cannabis brands in Australia, and this launch reinforces Aurora's commitment to providing accessible, high-quality medical cannabis options to meet diverse patient needs. The new products maintain TGA-GMP standards through MedReleaf Australia, strengthening Aurora's position as a global leader in medical cannabis.

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company, has announced its upcoming fourth quarter and fiscal year 2025 earnings conference call scheduled for June 18, 2025, at 8:00 a.m. Eastern Time. The company will release its financial results before markets open on the same day. The conference call will be hosted by Executive Chairman and CEO Miguel Martin and CFO Simona King, featuring a question and answer session. Investors can access the webcast through Aurora's investor relations website.

Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), Canada's largest medical cannabis company, has announced its participation in TD Cowen's 9th Annual Future of the Consumer Conference in New York City. CFO Simona King will engage in a fireside chat and investor meetings on June 3, 2025, at 2:45pm EST.

The discussion, hosted by TD Cowen's VP of Equity Research Derek Lessard, will focus on Aurora's international market expansion, medical cannabis landscape developments, Canadian manufacturing progress, and market dynamics. A live audio webcast will be available, with replay access for approximately 90 days through Aurora's investor relations website.

Aurora Cannabis has completed a $3 million investment in its Pemberton, British Columbia manufacturing facility, now renamed to Aurora Alpine. The multi-year upgrades have significantly improved the facility's performance, combining proprietary genetics with advanced engineering to optimize cultivation conditions.

Key achievements include:

• Doubled yield and potency, reaching 33.7% record levels
• GACP certification enabling international exports
• Enhanced operational efficiency and cultivation precision

The facility, formerly known as Whistler Medical Marijuana Company, was licensed in 2019. Located overlooking Mount Currie in the Pemberton Valley, the renamed Aurora Alpine reflects the company's commitment to excellence in cannabis production. The improvements strengthen Aurora's position as a global leader in medical cannabis, particularly in international markets through its premium product exports.

Aurora Cannabis (NASDAQ: ACB) has launched its first medical cannabis concentrates for patients in the United Kingdom, expanding its global medical cannabis portfolio. The company introduced two proprietary cultivar-specific 1.2g resin cartridges: Sourdough (indica) and Electric Honeydew (sativa).

The inhalable cartridges offer key benefits including exceptional flavor profiles, high potency for consistent dosing, and a user-friendly design for convenient and discreet consumption. The products are manufactured in TGA-GMP certified facilities without additives, ensuring premium quality and safety standards.

This launch follows successful implementations in Canada and Australia, demonstrating Aurora's commitment to expanding patient access to high-quality medical cannabis globally. The products are available nationwide through cannabis retailers, with patients advised to consult their doctors or clinics for more information.

Aurora Cannabis (NASDAQ: ACB) has been recognized on The Globe & Mail's 2025 Report on Business Women Lead Here list for its outstanding executive gender diversity. The company, Canada's largest medical cannabis provider, boasts 43% female representation in its executive leadership team.

The recognition highlights Aurora's commitment to diversity and inclusion, as emphasized by CFO Simona King. In 2022, the company established the Women Empowerment Network (WEN), an employee resource group focused on advancing women's professional development through learning and community engagement opportunities.

This achievement will be featured in the April 2025 issue of Report on Business magazine, distributed with The Globe and Mail on March 29, 2025.